Results 241 to 250 of about 273,925 (284)

Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer. [PDF]

Int J Mol Sci
Thu KL, Jafari S, Silvester J, Cruickshank J, Soria-Bretones I, Hodgson K, Tobin C, Haight J, Lau APY, Bray T, Wakeham D, Bray MR, Mak TW, Cescon DW.   +13 more
europepmc   +1 more source

Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer. [PDF]

J Exp Clin Cancer Res
Hellkamp M, Gertken S, Buchloh J, Hellwig JL, Kowitzke LB, Duan N, Gaspardo I, Küffer S, Linnebacher M, Ströbel P, Wirth M, Ellenrieder V, Rieken S, Gaedcke J, Ghadimi M, Wienands J, Schneider G, Spitzner M, Grade M.   +18 more
europepmc   +1 more source

HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence. [PDF]

J Immunother Cancer
Zhang X, Huang L, Li J, Cai Y, Chen W, Ren Y, Yuan X, Sun W, Sun S, Chu Q.   +9 more
europepmc   +1 more source

Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension. [PDF]

JACC CardioOncol
Ali HR, Faiz SA, Deswal A, Palaskas N, Iliescu C, Thompson K, Ohanian M, Pemmaraju N, Bose P, Sahay S.   +9 more
europepmc   +1 more source

Architectural Refuges: Mapping Spatial Heterogeneity and Niche-Mediated Drug Resistance in Gastric and Esophageal Adenocarcinomas. [PDF]

Cancers (Basel)
Thangaretnam K, Islam MO, Lv J, Chen L, Ballout F, Zhu S, Lu H, Peng D, El-Rifai W, Chen Z.   +9 more
europepmc   +1 more source

RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. [PDF]

Mol Biomed
Yao X, Lin Y, Chen P, Xu M, Pei M, Fan X, Feng H, Xing X, Guo J, Liu Y, Quan X, Pan Y, Tan Y, Zhou H, Dong L, Wang H, Hu H.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ncRNAs associated with drug resistance and the therapy of digestive system neoplasms

Journal of Cellular Physiology, 2019
AbstractDigestive system cancer remains a common cancer and the main cause of cancer‐related death worldwide. Drug resistance is a major challenge in the therapy of digestive system cancer, and represents a primary obstacle in the treatment of cancer by restricting the efficiency of both traditional chemotherapy and biological therapies.
Wei Feng, Zhangyao Su, Qingqing Yin, Wei Zong, Xianjuan Shen, Shaoqing Ju   +5 more
openaire   +2 more sources

[Correlation between C219 and drug resistance in lung neoplasms].

Minerva medica, 1993
The authors take into consideration 19 cases of lung neoplasm to see the relationship of clinical behaviour and C219. They found a cutoff (25%) to separate drug resistant by drug sensibility. Marker sensitivity was 84.2% and relation with PCNA was negative (-0.384).
G, Oddi, G, De Angelis, M G, Alma, F, De Marinis, D, Bigioni   +4 more
openaire   +1 more source

The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

Cancer research, 1984
Drug resistance continues to be a major factor in limiting the effectiveness of cancer chemotherapy. Evidence from a variety of sources implicates a genetic basis for most drug-resistant phenotypes. Assuming a random spontaneous origin for these resistant cells, it is possible to develop mathematical and computer-based models of the drug treatment of ...
J H, Goldie, A J, Coldman
openaire   +1 more source